Literature DB >> 26684870

Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.

Marinos C Dalakas1,2.   

Abstract

Mesh：

Year:  2016        PMID： 26684870      PMCID： PMC4720665          DOI： 10.1007/s13311-015-0414-2

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


× No keyword cloud information.
  15 in total

Review 1.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 4.  Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.

Authors:  Afsaneh Shirani; Darin T Okuda; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 5.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 6.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 7.  Neuroimmunotherapy: a practical approach to the treatment of immune-mediated neurologic diseases.

Authors:  M C Dalakas
Journal:  Semin Neurol       Date:  1994-06       Impact factor: 3.420

Review 8.  Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Authors:  Harry Alexopoulos; Angie Biba; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 9.  Future perspectives in target-specific immunotherapies of myasthenia gravis.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

Review 10.  Immunotherapies for Immune-Mediated Myopathies: A Current Perspective.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.